Navigation Links
Market testing of dietary supplements and drugs underscores value of USP's public health programs

Rockville, Md., November 12, 2007 On September 10, 2007, issued a report stating that several multivitamin supplements did not contain label amounts of folic acid. One of these products, B-50 Tablets, manufactured by IVC, Industries, Inc., is part of U. S. Pharmacopeias (USP) Dietary Supplement Verification Program and carries the USP Verified mark. In response to the report, USP studied the verified product to confirm the announced results. USPs testing found that the B-50 Tablets do in fact contain the required amount of folic acid, as claimed on the products label. The testing also demonstrated that the tablet in question meets USP dissolution requirements. USPs analysis showed that using appropriate test methods for the type of material under assessment, as provided in the United States Pharmacopeia and National Formulary (USPNF), is key to getting accurate results.

The importance of ongoing testing of dietary supplements to a public monograph is hard to overstate, said Roger L. Williams, M.D., executive vice president and CEO of USP. For this reason, USP acknowledges ConsumerLab.coms marketplace surveillance efforts. At the same time, these efforts require careful follow-up, which USP was able to do via its USP Verified agreement with the manufacturer of the B-50 Tablets. USP understands that further studies may be conducted by manufacturers and the Food and Drug Administration (FDA) based on the September 10 report.

The USP Verified program for dietary supplements and their ingredients provides a rigorous array of tests, resulting in manufacturer and consumer confidence that whats on the label is whats in the bottle. Via its voluntary, fee-based agreements with manufacturers, USP has a continuing commitment to monitor the quality of verified ingredients and products. USP was pleased to be able to clarify some of the findings of

In a separate report dated October 12, 2007, called into question the therapeutic interchangeability of two marketed extended release formulations of Buproprion Hydrochoride. For these drugs, primary responsibility for original and continuing market availability rests with the FDA working with manufacturers. USP notes that it does have drug product monographs for the involved formulations in the United States Pharmacopeia and that these monographs allow different dissolution requirements. This is appropriate on the assumption that the FDA has reviewed and found acceptable bioequivalence studies for formulations conforming to the monographs. USP does not verify drug products approved by the FDA.


Contact: Sandra Kim
US Pharmacopeia

Related biology news :

1. New study warns limited carbon market puts 20 percent of tropical forest at risk
2. Emerging (disease) markets
3. M2SYS Partners with SecuGen Corporation to Support Market Leading Hamster Plus Fingerprint Reader with Auto-On Technology
4. IEEE-USA innovation forum will help prepare US tech leaders to prosper in a global marketplace
5. Ceres and Texas A&M to develop and market high-biomass sorghum for biofuels
6. Safe water: simpler method for analyzing radium in water samples cuts testing time
7. Genetic ancestral testing cannot deliver on its promise, study warns
8. ACT Ensures Integrity of Testing Process Through Deployment of BIO-keys(R) Biometric ID Technology
9. UF scientists reveal how dietary restriction cleans cells
10. Dietary calcium could possibly prevent the spread of breast cancer to bone
11. Changing the global dietary environment
Post Your Comments:
(Date:10/26/2015)... , October 26, 2015 /PRNewswire/ ... --> adds Biometrics ... to 2021 as well as Emerging ... research reports to its collection of ... . --> ...
(Date:10/23/2015)... 23, 2015 Research and Markets ( ... Voice Recognition Biometrics Market 2015-2019" report to their ... The global voice recognition biometrics market to grow ... --> --> The report, ... based on an in-depth market analysis with inputs from ...
(Date:10/22/2015)... Calif., Oct. 22, 2015  Synaptics (NASDAQ: SYNA ), a ... its first quarter ended September 30, 2015. ... of fiscal 2016 grew 66 percent over the comparable quarter last ... fiscal 2016 was $23.8 million, or $0.62 per diluted share. ... for the first quarter of fiscal 2016 grew 39 percent over ...
Breaking Biology News(10 mins):
(Date:11/27/2015)... ... 2015 , ... Pittcon is pleased to announce the 2016 ... symposia, oral sessions, workshops, awards, and posters. The core of the Technical ... as, but not limited to, biotechnology, biomedical, drug discovery, environmental, food science, fuels/energy, ...
(Date:11/26/2015)... 26, 2015 ... Accutest Research Laboratories, a leading independent ... (CRO), has formed a strategic partnership ... Temple Health for joint work on ... ) , --> ...
(Date:11/25/2015)... 2015 --> ... - 2020 report analyzes that automating biobanking workflow ... in long-term samples, minimizing manual errors, improving the ... manual errors such as mislabeling or inaccurate sample ... plays a vital role in blood fractionation, DNA ...
(Date:11/25/2015)... 2 nouvelles études permettent d , identifier ... souches bactériennes retrouvées dans la plaque dentaire des ... Ces recherches  ouvrent une nouvelle voie ... l,un des problèmes de santé les plus fréquemm ... --> 2 nouvelles études permettent d , ...
Breaking Biology Technology: